Roche Diagnostics and deCODE unveil broad new alliance

07-Mar-2001

Roche diagnostics and deCODE genetics (Nasdaq/Easdaq:DCGN) today announced the signing of a letter of intent to establish a broad new alliance in the field of DNA-based diagnostics. The two companies will use deCODE’s genomics research and informatics resources to develop an integrated suite of new diagnostic products and services for diagnosing common diseases and predicting individual predisposition in order to create more effective treatment and prevention regimes. Over the five-year term of the alliance, to run from 2001–2006, Roche will provide deCODE with a major package of committed research funding, potential milestone payments and product royalties. The two companies intend to begin work under the present terms of the alliance effective immediately. The alliance builds on key Roche and deCODE assets: Roche Diagnostics’ global leadership in the field of molecular diagnostics and deCODE’s unique population genomics resources and bioinformatics expertise. In addition to the development of novel DNA-based diagnostic and predisposition screening products, the partners intend to develop point-of-care informatics products and services. These will assist doctors and their patients in evaluating DNA-based diagnostic test results, with the aim of supporting medical decision-making and optimizing the possibilities for the early treatment and prevention of disease. This new agreement will thus complement the companies’ 1998 gene discovery collaboration by targeting new diseases and bringing deCODE’s research and expertise to bear directly on the process of product development. The Head of Roche Diagnostics, Heino von Prondzynski, said: “By bringing together our research programmes and market leadership with deCODE’s integrated approach to the genetics of common diseases, we hope to create a new paradigm for the use of DNA-based diagnostics in the treatment and prevention of these diseases.” Kari Stefansson, CEO of deCODE genetics, added: “It is very exciting to be able to bring together our gene research and bioinformatics know-how for the development of the next generation in diagnostic tools and decision support systems. We will also be working with a trusted partner and the world leader in the field of diagnostics.”

https://www.chemeurope.com/en/news/1719/roche-diagnostics-and-decode-unveil-broad-new-alliance.html